OAM
LEGN icon

Oberweis Asset Management’s Legend Biotech LEGN Stock Holding History

Oberweis Asset Management’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6,000
Closed -$337K – 209
2024
Q1 		$337K Sell
6,000
-10,000
-63% -$603K 0.02% 184
2023
Q4 		$963K Hold
16,000
– – 0.09% 174
2023
Q3 		$1.07M Buy
16,000
+4,000
+33% +$278K 0.11% 172
2023
Q2 		$828K Buy
+12,000
New +$784K 0.1% 164

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Oberweis Asset Management's LEGN Position: Q2 2024 in Review

Oberweis Asset Management sold out of Legend Biotech (LEGN) in Q2 2024, closing a stake of 6,000 shares — an estimated $337K sold.

Oberweis Asset Management first reported a position in LEGN in Q2 2023 and held it in 4 quarters. The position peaked at $1.07M in Q3 2023. 181 funds tracked by Wall St. Rank hold LEGN as of Q2 2024.

  • Oberweis Asset Management reported no remaining Legend Biotech position as of Q2 2024 after selling out during the quarter.
  • Oberweis Asset Management sold 6,000 Legend Biotech shares in Q2 2024, an estimated $337K.
  • Oberweis Asset Management first reported a position in Legend Biotech in Q2 2023 and held it in 4 quarters.
  • Oberweis Asset Management's Legend Biotech position peaked at $1.07M in Q3 2023.
  • 181 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2024.

Based on Oberweis Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.